Abstract
Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) are the two most common forms of dementia due to neurodegeneration. AD is characterized by extracellular amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles, whereas DLB is defined by α-synuclein (α-Syn)-containing Lewy bodies. Although AD and DLB exhibit divergent core features, the disorders frequently co-occur and converge on shared endpoints. Co-pathology is common and linked to more severe cognitive decline, faster progression, and clinicopathological heterogeneity. Here, we discuss the current understanding of shared and unique clinical and neuropathological features of AD and DLB. We compare genetic risk and pathological drivers (Aβ and tau in AD; α-Syn in DLB) and their overlapping co-pathology, and review downstream mechanisms—mitochondrial dysfunction, oxidative stress, neuroinflammation, and cerebrovascular contributions, including cerebral amyloid angiopathy. We highlight recent findings from state-of-the-art multi-omics (transcriptomic, proteomic, metabolomic, and single-cell/spatial studies) that reveal convergent and disease-specific molecular signatures of AD and DLB. We outline a framework for emerging next-generation biomarkers—from blood-based and cerebrospinal fluid assays to imaging and digital measures—for diagnosis and stratification, and discuss potential translational implications. Together, these advances help to disentangle shared from disease-specific mechanisms, which is essential for improved diagnosis and the development of precise, disease-modifying therapies.
1. Introduction
On 3 November 1906, at a German psychiatrists meeting in Tübingen, Germany, Alois Alzheimer, a psychiatrist and neuropathologist gave a talk on “A peculiar severe disease process of the cerebral cortex”, describing a woman named Auguste Deter with symptoms of presenile dementia, and reported the post-mortem autopsy of her brain that showed senile plaques and neurofibrillary tangles [1,2]. A few years later in 1910, Emil Kraepelin, a German psychiatrist, named the disease condition “Alzheimer’s disease” [3,4]. Alzheimer’s disease (AD) is the most common progressive neurodegenerative disorder caused by neuronal cell death. AD currently affects around 50 million patients globally and this number is projected to reach approximately 152 million by 2050 [5,6]. According to global burden-of-disease estimates, AD and other dementias accounted for 25.3 million disability-adjusted life years (DALYs) worldwide in 2019, increased from 9.66 million DALYs in 1990, reflecting a substantial rise over this period [7,8,9]. AD is prevalent among adults aged 65 years or older, and has a life expectancy of about 3–10 years [10]. Depending on the stage, AD patients often exhibit a severe decline in cognitive and behavioural ability, initially with memory and spatial navigation problems, and other symptoms such as executive dysfunction (planning/organization), impaired reasoning and judgement, attention and concentration problems, personality and behaviour changes, mood changes, social withdrawal, agitation and aggression, paranoia/delusions, and sleep disturbances [11,12,13,14].
Early stage AD exhibits histological alterations and atrophy in the entorhinal cortex within the hippocampus of the medial temporal lobe, a brain region crucial for episodic memory formation and consolidation and spatial navigation [15,16,17]. Biochemists George Glenner and Caine Wong reported the accumulation of a 4 kDa peptide, which they termed “amyloid-β protein” (Aβ), the major constituent of extracellular amyloid plaques [18,19]. Similarly, Inge Grundke-Iqbal and Khalid Iqbal identified microtubule-associated protein tau (MAPT) in some neurofibrillary tangles and plaque neurites in the AD brain [20,21].
Dementia with Lewy bodies (DLB) is an age-associated neurodegenerative disorder that is less common than AD [22]. DLB is a member of a group of neurodegenerative diseases referred to as synucleinopathies, which also include Parkinson’s disease (PD) and multiple system atrophy (MSA). Synucleinopathies are a group of disorders characterized by pathological accumulation of the misfolded form of the small presynaptic protein alpha-synuclein (α-Syn), which is encoded by the gene SNCA. Major synucleinopathies are Lewy body diseases (LBDs) [23]. LBDs refer to a group of disorders comprising Parkinson’s disease (PD), Parkinson’s disease dementia (PDD), and dementia with Lewy bodies (DLB), which share the neuropathological hallmark of deposition of Lewy bodies within neurons and extensive axonal Lewy neurites [24,25]. However, among synucleinopathies, MSA is characterized by accumulation of inclusions known as glial cytoplasmic inclusions containing synuclein aggregates in oligodendrocytes, while Lewy body pathology is absent and, therefore, the LBD group does not include MSA [24,26,27,28].
DLB has an incidence of 0.5–1.6 per 1000 person-years and affects an estimated 1.4 million people in the United States [29]. It accounts for ~7.5% of all dementia cases [30]. DLB typically begins in the late fifties and constantly increases with age [31,32], and it is more prevalent in males than females [33]. Historically, in 1912, Jakob Heinrich Lewy, who was studying Parkinson’s disease at Alois Alzheimer’s laboratory, observed eosinophilic intraneuronal inclusion bodies, which were named Lewy bodies by Nikolaevich Tretiakoff in 1919 [34]. DLB gained momentum in 1961, when Okazaki et al. reported that patients with dementia who died shortly thereafter and had severe extrapyramidal rigidity [35]. Later, Japanese psychiatrist Kenji Kosaka and colleagues observed Lewy bodies in the brainstem and cerebral cortex in post-mortem autopsy samples from more than 20 patients with different types of cognitive impairment [36,37]. In 1995, the term “dementia with Lewy bodies” was first proposed at the First International Workshop (Newcastle upon Tyne, England), with the diagnostic criteria focused on three core features: impairment in cognitive function, hallucinations, and Parkinsonian features [36,38,39]. In 1997, Spillantini and colleagues identified α-Syn as a major component of Lewy bodies in the brain tissue from patients with DLB and PD [40].
AD and DLB frequently converge clinically and pathologically, complicating diagnosis, prognostication, medication selection, and eligibility for clinical trials. In this review, we briefly compare the clinical and neuropathological features of AD and DLB. We integrate evidence across fluid biomarkers, genetics, and imaging to delineate shared versus disease-specific biology. Finally, we translate the evidence from the findings into therapeutic implications and outline new future research directions with potential next steps for targeted treatments.
2. Clinical and Neuropathological Overlap Between AD and DLB
2.1. Clinical Features of AD
AD usually co-exists with ageing and presents with cognitive, behavioural, and psychological symptoms. In the early stage, individuals with AD show amnestic features such as memory loss, trouble learning new information, repeating questions, misplacing items, and difficulty with spatial navigation [14,41]. As the disease progresses, the moderate stage includes memory loss; disorientation of time and place; language difficulties; and impaired executive function such as poor reasoning and planning, with changes in mood (apathy, irritability, or depression), difficulty in solving complex daily tasks, and impaired judgement. In the late stages, AD patients show global cognitive failure, dependency for activities of daily living, gait impairment, dysphagia, and other complex neurological and psychiatric symptoms such as agitation, delusions or occasional hallucinations, and extrapyramidal symptoms such as rigidity or gait disturbance [14,42]. Initially, in 1984, the criteria were set by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS–ADRDA criteria for AD) as a suitable procedure for the clinical diagnosis of AD and have recently been updated [43,44,45]. The National Institute on Aging and Alzheimer’s Association (NIA–AA) updated the clinical approach guidelines, introduced the use of biomarkers, and proposed a new biological scheme: amyloid, tau, neurodegeneration (A/T(N)) for research [46]. In day-to-day practice, clinicians still diagnose the disease based on medical records, physical and neurological examinations, neuropsychological evaluation, and neuroimaging [47].
2.2. Clinical Features of DLB
Individuals with DLB also show cognitive impairment with characteristic non-amnestic features that often different from those of typical AD. The major symptoms of DLB are progressive cognitive or visuospatial impairment with fluctuating attention and alertness, parkinsonism (rigidity, slowness, tremor, shuffling gait, and falls), recurrent visual hallucinations, REM sleep behaviour disorder (RBD), and antipsychotic sensitivity causing worse parkinsonism, confusion, and sleepiness [48,49]. In the later stages, DLB patients commonly develop autonomic instability (orthostatic hypotension and urinary incontinence), repeated falls, and increased sensitivity to antipsychotics [33]. The 2017 DLB Consortium criteria diagnose probable DLB if there are two or more core clinical features, or one core feature plus an indicative biomarker (reduced striatal dopamine-transporter uptake (positron emission tomography/single-photon emission computed tomography, PET/SPECT), reduced myocardial iodine-123-metaiodobenzylguanidine (MIBG) uptake, or polysomnographic confirmation of rapid eye movement (REM) sleep without atonia) [22,50,51]. Many symptoms of DLB overlap with those of PD; hence, the timing of the symptoms is diagnostically crucial. According to the “1-year rule”, dementia that begins before or within 1 year of the onset of parkinsonism helps separate DLB from PDD. DLB is favoured when dementia precedes or appears within 1 year of the onset of parkinsonism [38,50,52,53].
AD and DLB have some distinct early symptoms that can help differentiate them. AD starts with prominent episodic memory loss, a steady decline, and spatial navigation deficits, and features like hallucinations or parkinsonism usually appear late [47,54]. However, in DLB, early visual hallucinations, fluctuating cognitive features, RBD, and parkinsonism are hallmarks; autonomic failure and marked antipsychotic sensitivity increase the diagnostic confidence for DLB [55,56]. On bedside testing, DLB shows visuospatial and attentional deficits disproportionate to memory impairment, whereas AD is characterized by predominant amnestic deficits. The timing of motor signs is important: parkinsonism near or preceding cognitive symptoms supports DLB, while late parkinsonism in a prolonged amnestic course favours AD with superimposed extrapyramidal signs [57]. Recognition of these discriminators reduces misdiagnosis and avoids toxic antipsychotic exposure in DLB. Overall, although almost the same neurological and psychiatric symptoms may occur in AD and DLB, there are differences in time of onset, prevalence, and severity during the disease course [58,59]. Cases with multiple co-pathologies are associated with increased odds of late-onset hallucinations [59]. Memory loss is the most prevalent early sign in AD, whereas in DLB, other cognitive symptoms (planning, judgement, and problem solving) prevail as the presenting sign. Movement disorders, hallucinations, sleep disorders, fluctuations in alertness and attention, and autonomic nervous system impairment signs (orthostatic hypotension, urinary incontinence) are more frequent and have an earlier onset in DLB than in AD.
2.3. Neuropathological Features of AD
At the autopsy, AD brains often show moderate cerebral cortical atrophy primarily with narrowed gyri and widened sulci, early and significant atrophy of the medial temporal lobe (hippocampal/entorhinal atrophy), and symmetrical dilation of the lateral ventricles (hydrocephalus ex vacuo) compared with healthy age-matched controls [60,61,62]. Microscopically, AD brains show accumulation of extracellular Aβ (diffuse and neuritic) and intraneuronal neurofibrillary tangles composed of hyperphosphorylated tau [63,64,65]. In a landmark study by Braak H. and Braak E., tau pathology progresses in a predictable Braak sequence: transentorhinal (Stage I–Stage II) → limbic/hippocampal (Stage III–Stage IV) → widespread neocortical (Stage V–Stage VI), tracking clinical severity; Aβ deposition follows Thal phases from neocortex to deeper structures [66,67,68,69]. Thal phases (1–5) stage the spread of amyloid-β plaques in AD: starting in the neocortex (1), then hippocampal/allocortical regions (2), striatum and diencephalon (3), brainstem (4), and finally the cerebellum (5) [69]. Neuroinflammatory changes such as activated microglia and astrocytosis, together with synaptic loss and neuronal death, accompany these lesions, and tangle burden correlates with cognitive impairment [60]. Current NIA–AA neuropathologic guidelines report “AD neuropathologic change” on a continuum, integrating Braak neurofibrillary tangle stage, Thal Aβ phase, and neuritic plaque scores [70].
2.4. Neuropathological Features of DLB
DLB brains also show cortical atrophy, but it is less severe than in AD [24]. Most prominently in early stages, for instance in the medial temporal lobe (hippocampus), atrophy is more profound in AD patients than in DLB. DLB patients show Lewy pathology, which is observed in the brainstem (mainly the substantia nigra), limbic, and neocortical regions [71]. DLB brains mainly exhibit depigmentation of the substantia nigra and locus coeruleus due to loss of the majority of pigmented neurons. In later stages, DLB individuals’ brains show moderate cortical atrophy [24,72,73,74]. Microscopically, DLB patients show two general types of Lewy bodies: classic brainstem Lewy bodies with a dense eosinophilic core and a pale halo (visible by haematoxylin and eosin staining), and cortical Lewy bodies, which are smaller, lack the halo, and are mainly observed by α-Syn immunohistochemistry. α-Syn is the primary component of Lewy bodies [25,75,76]. However, post-mortem studies of DLB brains suggest that microglial activation is not prominent in DLB compared to AD [77].
Comparatively, DLB post-mortem tissue shows widespread cortical and limbic α-Syn-containing inclusions, whereas AD shows medial temporal (hippocampal) atrophy with abundant neuritic Aβ plaques and high-stage tau tangles.
Co-pathology is common, but lesion type, regional burden, and staging (Braak/Thal) usually distinguish the two [24,78,79,80]. Pure phenotypes have exclusively either AD or DLB pathology, whereas mixed phenotypes present with both based on the standard neuropathological examination protocols. The high proportion of mixed AD + DLB cases and prevalence of other co-pathologies negatively influence the accuracy of clinical diagnosis versus neuropathology, with implications for clinical trial enrolment and evaluation [81].
An overview of the shared versus disease-specific features is shown in Figure 1.
Figure 1.
Comparison of shared and discriminating features of AD and DLB. Left hemisphere (AD-predominant): extracellular Aβ plaques and intraneuronal tau tangles accompanied by medial–temporal and cortical atrophy and ventriculomegaly. Right hemisphere (DLB-predominant): α-synuclein Lewy bodies and neurites in brainstem (substantia nigra, locus coeruleus). The middle circular band summarizes the shared features: mitochondrial dysfunction/oxidative stress, neuroinflammation, cerebrovascular/BBB, and synaptic/proteostasis–lysosome–autophagy stress. The bottom boxes summarize the core clinical profiles and indicative biomarkers for AD and DLB. AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; Aβ, amyloid-β; α-Syn, α-synuclein; DAT, dopamine transporter; GFAP, glial fibrillary acidic protein; LBV, Lewy body variant of AD; NfL, neurofilament light; RT-QuIC, real-time quaking-induced conversion; PMCA, Protein Misfolding Cyclic Amplification; DAT-SPECT, dopamine transporter single-photon emission computed tomography. Downward (↓) arrows indicate decreases in protein levels or uptake.
4. Emerging Next-Generation Biomarkers
The current well-established tools for diagnosing AD are CSF biomarkers and neuroimaging. Imaging techniques include advanced PET, such as Aβ-PET (used to visualize Aβ deposition) and tau-PET (used to assess tau pathology), which is used together with 18F-fluorodeoxyglucose (18F-FDG) PET and structural magnetic resonance imaging (MRI). The latter two serve as indicators of neurodegeneration [164,165]. Major reliable CSF and advanced blood-based biomarkers for pathological changes in AD are Aβ42 (often expressed as the Aβ42/Aβ40 ratio), total tau, phosphorylated tau, neurofilament light chain (NfL), the microRNA subtypes miR-21-5p and miR-451a, and glial fibrillary acidic protein (GFAP) [166,167].
Beyond Aβ and tau, other non-traditional, minimally invasive alternative biomarkers (such as salivary biomarkers (e.g., lactoferrin and acetylcholinesterase), urinary biomarkers (AD7c neuronal thread protein and extracellular vesicle proteins), lipidomic shifts (ceramide/sphingomyelin), synaptic/axonal proteins (neurogranin), circulating microRNAs, and gut/fecal-derived readouts that reflect inflammation, synaptic injury, mitochondrial stress, and membrane lipid dysregulation) can be used to enhance diagnostic accuracy [168] and their use signals a shift to multi-dimensional biomarker assessments. Polykretis et al. demonstrated that atomic force microscopy (AFM) can directly visualize fibrillar structures in crude CSF from patients with AD and other neurological conditions and proposed these features as candidate biomarkers of blood–brain barrier injury and disease progression. However, pre-analytical/analytical harmonization and throughput remain barriers to clinical adoption [169].
Interestingly, detection of spatial navigation ability using the Sea Hero Quest smartphone game is emerging as a sensitive, early “cognitive fingerprint” of AD risk. In large, real-world large demographic samples, navigation performance can flag preclinical risk and has been reported to outperform some standard memory tests, positioning it as an early digital biomarker [41,170].
The well-known current clinical practices for diagnosing DLB are (i) 123I-FP-CIT dopamine transporter SPECT (DAT-SPECT) for nigrostriatal uptake, (ii) polysomnography for REM sleep without atonia, and (iii) 123I-MIBG cardiac scintigraphy showing reduced cardiac uptake. DAT SPECT offers high specificity; however, it has only moderate sensitivity in prodromal stages [171]. A new line of research has offered a method for detection of α-Syn in biological samples as an additional avenue for biomarker development [172]. α-Syn seed amplification assays (SAAs) such as RTQuIC (Real-Time Quaking-Induced Conversion) and PMCA (Protein Misfolding Cyclic Amplification) show high sensitivity and specificity for detecting PD in CSF samples and hold promise for stratifying synucleinopathies, including DLB, using seeded aggregation kinetics [173]. No blood test has been clinically validated for DLB, although plasma/exosomal α-Syn are under study and some non-traditional matrices, including SAAs for peripheral tissues and body fluid olfactory mucosa and urine, have shown poor agreement with CSF results [174].
Sjaelland and colleagues performed a systematic review that screened 4295 records and included 20 studies and reported that 17 different portable and wearable digital health technologies have been used to capture digital biomarkers of non-cognitive symptoms in DLB, but validation and feasibility reporting remain uncertain. Future digital biomarker–related studies with standardized evaluation are needed before adoption for clinical use [175].
A multiplex approach that integrates core clinical features with neuroimaging and fluid biomarkers is needed to improve the diagnostic accuracy of DLB [176,177]. Beyond diagnostic A/T(N) panels and α-Syn SAAs, prognosis may be informed by nanoscale, label-free readouts from biofluids. Marcuello et al. reviewed AFM platforms that capture the morphology, mechanics, and chemistry of protein assemblies at the single-particle resolution, highlighting their potential to quantify pathological aggregates [178]. If standardized and longitudinally validated (e.g., particle counts, length distributions, and nanomechanical signatures), such AFM-based metrics could complement conventional Aβ/tau/α-Syn measures for risk stratification and pharmacodynamic monitoring, including in DLB. Given the complex nature of AD and DLB pathobiology, no single marker can fully capture disease progression across all stages. Combined use of fluid biomarkers with imaging biomarkers and emerging new biomarkers can provide comprehensive biological insights. Using fluid and imaging measures together provides multilevel insights that better support precision diagnosis and prognosis and treatment monitoring, thereby offering new opportunities for earlier diagnosis and more effective disease management.
5. Conclusions and Therapeutic Future Directions
The increasing number of cases of AD and DLB impose steep and rising societal and economic burdens such as caregiver stress and health-system costs. Despite impressive progress in the field, disease-modifying options remain limited aside from recently approved anti-amyloid monoclonal antibodies for AD [179], so there is an urgent need for therapies that halt progression. AD and DLB frequently co-occur and share pathology, complicating diagnosis, prognosis, and medication choice. Hence, it is important to investigate the contribution of co-pathology in each patient. Determining whether a patient has pure AD, pure DLB, or a mixed phenotype is crucial for clinical trial selection and interpretation.
While established imaging and CSF tests are valuable, the current biomarker toolkit for distinguishing mixed versus pure disease is still incomplete. Larger, longitudinal, and standardized studies involving α-Syn SAAs, A/T(N) panels, proteomic/metabolomic signatures, peripheral or blood-based signatures, and rigorously validated digital biomarkers could help in clarifying these complex questions. Leveraging patient-derived induced pluripotent stem cells (iPSCs) and advanced brain organoid models that recapitulate α-Syn, tau, and Aβ pathologies will accelerate target discovery and mechanism-driven pharmacology. High-throughput CRISPR perturbation platforms such as unbiased screens [180] should be used to reveal druggable targets. Modern drug-design toolkits, such as computer-aided drug design, integrative drug design approaches [181], enhanced targeted protein degradation (e.g., PROTACs), molecular chaperone modulators, and peptide/binder design platforms such as BindCraft [182], can be deployed to design and identify selective modulators of α-Syn, tau, and their upstream trafficking/clearance machinery. Future studies should be directed at investigating a combinatorial treatment approach, such as pairing an anti-amyloid agent with an anti-α-Syn therapy, with or without an anti-tau component and other additional strategies for synaptic repair, mitochondrial support, glial-immune modulation, and neurovascular protection.
In conclusion, deeper investigation of the molecular mechanisms, particularly the synergistic interplay between Aβ, α-Syn, and tau, is needed to uncover the mechanisms underlying the overlapping pathology and points of divergence. Clarifying these networks will open up new avenues for earlier and more accurate diagnostics and for rational, mechanism-based therapeutic interventions.
Author Contributions
Conceptualization, Investigation, Writing—original draft: S.N. Visualization: S.N. Supervision, Writing—review and editing: T.H. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Data Availability Statement
No new data were created or analyzed in this study. Data sharing is not applicable to this article.
Conflicts of Interest
The authors declare no conflicts of interest.
Abbreviations
The following abbreviations are used in this manuscript:
| 18F-FDG | 18F-fluorodeoxyglucose |
| A/T(N) | amyloid/tau/neurodegeneration |
| Aβ | amyloid-β |
| AD | Alzheimer’s disease |
| ADNI | Alzheimer’s Disease Neuroimaging Initiative |
| AFM | atomic force microscopy |
| BBB | blood–brain barrier |
| BACE1 | β-site APP cleaving enzyme 1 |
| CAA | cerebral amyloid angiopathy |
| CSF | cerebrospinal fluid |
| CTF99 | C-terminal fragment 99 (of APP) |
| DALY | disability-adjusted life year |
| DAT-SPECT | dopamine transporter single-photon emission computed tomography |
| DLB | dementia with Lewy bodies |
| GFAP | glial fibrillary acidic protein |
| GWAS | genome-wide association studies |
| iPSC | induced pluripotent stem cells |
| LBD | Lewy body disease |
| LBV | Lewy body variant (of Alzheimer’s disease) |
| LMTK2 | Lemur Tyrosine Kinase 2 |
| MAPK | mitogen-activated protein kinase |
| MAPT | microtubule-associated protein tau |
| MIBG | metaiodobenzylguanidine |
| miR | microRNA |
| MRI | magnetic resonance imaging |
| MSA | multiple system atrophy |
| NfL | neurofilament light chain |
| NIA–AA | National Institute on Aging–Alzheimer’s Association |
| NINCDS–ADRDA | National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association |
| PD | Parkinson’s disease |
| PDD | Parkinson’s disease dementia |
| PET | positron emission tomography |
| PFF | pre-formed fibril |
| PheWASs | phenome-wide association studies |
| PMCA | Protein Misfolding Cyclic Amplification |
| RBD | REM sleep behaviour disorder |
| REM | rapid eye movement |
| RNA-seq | RNA sequencing |
| RT-QuIC | real-time quaking-induced conversion |
| SAA(s) | seed amplification assays |
| SPECT | single-photon emission computed tomography |
| TDP-43 | TAR DNA-binding protein 43 |
| TMT-MS | Tandem Mass Tag mass spectrometry |
| α-Syn | alpha-synuclein |
References
- Hippius, H.; Neundörfer, G. The Discovery of Alzheimer’s Disease. Dialogues Clin. Neurosci. 2003, 5, 101–108. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Thakor, V.S.; Tyagi, A.; Lee, J.M., Jr.; Coffman, F.; Mittal, R. Alois Alzheimer (1864–1915): The Father of Modern Dementia Research and the Discovery of Alzheimer’s Disease. Cureus 2024, 16, e71731. [Google Scholar] [CrossRef] [Scilit]
- Yang, H.D.; Kim, D.H.; Lee, S.B.; Young, L.D. History of Alzheimer’s Disease. Dement. Neurocognitive Disord. 2016, 15, 115. [Google Scholar] [CrossRef] [Scilit]
- Ciurea, V.A.; Covache-Busuioc, R.-A.; Mohan, A.G.; Costin, H.P.; Voicu, V. Alzheimer’s Disease: 120 Years of Research and Progress. JMedLife 2023, 16, 173–177. [Google Scholar] [CrossRef] [Scilit]
- Livingston, G.; Huntley, J.; Sommerlad, A.; Ames, D.; Ballard, C.; Banerjee, S.; Brayne, C.; Burns, A.; Cohen-Mansfield, J.; Cooper, C.; et al. Dementia Prevention, Intervention, and Care: 2020 Report of the Lancet Commission. Lancet 2020, 396, 413–446, Erratum in Lancet 2023, 402, 1132. [Google Scholar] [CrossRef] [Scilit]
- Xiaopeng, Z.; Jing, Y.; Xia, L.; Xingsheng, W.; Juan, D.; Yan, L.; Baoshan, L. Global Burden of Alzheimer’s Disease and Other Dementias in Adults Aged 65 Years and Older, 1991–2021: Population-Based Study. Front. Public Health 2025, 13, 1585711. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Steinmetz, J.D.; Seeher, K.M.; Schiess, N.; Nichols, E.; Cao, B.; Servili, C.; Cavallera, V.; Cousin, E.; Hagins, H.; Moberg, M.E.; et al. Global, Regional, and National Burden of Disorders Affecting the Nervous System, 1990–2021: A Systematic Analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024, 23, 344–381, Erratum in: Lancet Neurol. 2024, 23, e9. https://doi.org/10.1016/S1474-4422(24)00114-5. Erratum in: Lancet Neurol. 2024, 23, e11. https://doi.org/10.1016/S1474-4422(24)00231-X. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Li, X.; Feng, X.; Sun, X.; Hou, N.; Han, F.; Liu, Y. Global, Regional, and National Burden of Alzheimer’s Disease and Other Dementias, 1990–2019. Front. Aging Neurosci. 2022, 14, 937486. [Google Scholar] [CrossRef] [Scilit]
- Lin, C.-Y.; Zhai, Y.-J.; An, H.-H.; Wu, F.; Qiu, H.-N.; Li, J.-B.; Lin, J.-N. Global Trends in Prevalence, Disability Adjusted Life Years, and Risk Factors for Early Onset Dementia from 1990 to 2021. Sci. Rep. 2025, 15, 13488. [Google Scholar] [CrossRef] [Scilit]
- Liang, C.-S.; Li, D.-J.; Yang, F.-C.; Tseng, P.-T.; Carvalho, A.F.; Stubbs, B.; Thompson, T.; Mueller, C.; Shin, J.I.; Radua, J.; et al. Mortality Rates in Alzheimer’s Disease and Non-Alzheimer’s Dementias: A Systematic Review and Meta-Analysis. Lancet Healthy Longev. 2021, 2, e479–e488. [Google Scholar] [CrossRef] [Scilit]
- Barnes, J.; Dickerson, B.C.; Frost, C.; Jiskoot, L.C.; Wolk, D.; Van Der Flier, W.M. Alzheimer’s Disease First Symptoms Are Age Dependent: Evidence from the NACC Dataset. Alzheimer’s Dement. 2015, 11, 1349–1357. [Google Scholar] [CrossRef] [Scilit]
- Breijyeh, Z.; Karaman, R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules 2020, 25, 5789. [Google Scholar] [CrossRef] [Scilit]
- Förstl, H.; Kurz, A. Clinical Features of Alzheimer’s Disease. Eur. Arch. Psychiatry Clin. Neurosci. 1999, 249, 288–290. [Google Scholar] [CrossRef] [Scilit]
- Zvěřová, M. Clinical Aspects of Alzheimer’s Disease. Clin. Biochem. 2019, 72, 3–6. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Trejo-Lopez, J.A.; Yachnis, A.T.; Prokop, S. Neuropathology of Alzheimer’s Disease. Neurotherapeutics 2022, 19, 173–185. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Igarashi, K.M. Entorhinal Cortex Dysfunction in Alzheimer’s Disease. Trends Neurosci. 2023, 46, 124–136. [Google Scholar] [CrossRef] [Scilit]
- Tacikowski, P.; Kalender, G.; Ciliberti, D.; Fried, I. Human Hippocampal and Entorhinal Neurons Encode the Temporal Structure of Experience. Nature 2024, 635, 160–167. [Google Scholar] [CrossRef] [Scilit]
- Tanzi, R.E.; Bertram, L. Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective. Cell 2005, 120, 545–555. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Glenner, G.G.; Wong, C.W. Alzheimer’s Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein. Biochem. Biophys. Res. Commun. 1984, 120, 885–890. [Google Scholar] [CrossRef] [Scilit]
- Grundke-Iqbal, I.; Iqbal, K.; Tung, Y.-C.; Wisniewski, H.M. Alzheimer Paired Helical Filaments: Immunochemical Identification of Polypeptides. Acta Neuropathol. 1984, 62, 259–267. [Google Scholar] [CrossRef] [Scilit]
- Grundke-Iqbal, I.; Iqbal, K.; Tung, Y.C.; Quinlan, M.; Wisniewski, H.M.; Binder, L.I. Abnormal Phosphorylation of the Microtubule-Associated Protein Tau (Tau) in Alzheimer Cytoskeletal Pathology. Proc. Natl. Acad. Sci. USA 1986, 83, 4913–4917. [Google Scholar] [CrossRef] [Scilit]
- Capouch, S.D.; Farlow, M.R.; Brosch, J.R. A Review of Dementia with Lewy Bodies’ Impact, Diagnostic Criteria and Treatment. Neurol. Ther. 2018, 7, 249–263. [Google Scholar] [CrossRef] [Scilit]
- Goedert, M.; Jakes, R.; Spillantini, M.G. The Synucleinopathies: Twenty Years On. J. Park. Dis. 2017, 7, S51–S69. [Google Scholar] [CrossRef] [Scilit]
- Outeiro, T.F.; Koss, D.J.; Erskine, D.; Walker, L.; Kurzawa-Akanbi, M.; Burn, D.; Donaghy, P.; Morris, C.; Taylor, J.-P.; Thomas, A.; et al. Dementia with Lewy Bodies: An Update and Outlook. Mol. Neurodegener. 2019, 14, 5. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Hasegawa, M.; Goedert, M. α-Synuclein in Filamentous Inclusions of Lewy Bodies from Parkinson’s Disease and Dementia with Lewy Bodies. Proc. Natl. Acad. Sci. USA 1998, 95, 6469–6473. [Google Scholar] [CrossRef] [Scilit]
- Jellinger, K.A. Neuropathological Spectrum of Synucleinopathies. Mov. Disord. 2003, 18, 2–12. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jellinger, K.A.; Lantos, P.L. Papp–Lantos Inclusions and the Pathogenesis of Multiple System Atrophy: An Update. Acta Neuropathol. 2010, 119, 657–667. [Google Scholar] [CrossRef] [Scilit]
- Jellinger, K.A. Heterogeneity of Multiple System Atrophy: An Update. Biomedicines 2022, 10, 599. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Galvin, J.E.; Chrisphonte, S.; Cohen, I.; Greenfield, K.K.; Kleiman, M.J.; Moore, C.; Riccio, M.L.; Rosenfeld, A.; Shkolnik, N.; Walker, M.; et al. Characterization of Dementia with Lewy Bodies (DLB) and Mild Cognitive Impairment Using the Lewy Body Dementia Module (LBD-MOD). Alzheimer’s Dement. 2021, 17, 1675–1686. [Google Scholar] [CrossRef] [Scilit]
- Vann Jones, S.A.; O’Brien, J.T. The prevalence and incidence of dementia with Lewy bodies: A systematic review of population and clinical studies. Psychol. Med. 2014, 44, 673–683, Erratum in: Psychol. Med. 2014, 44, 684. [Google Scholar] [CrossRef] [Scilit]
- Wakisaka, Y.; Furuta, A.; Tanizaki, Y.; Kiyohara, Y.; Iida, M.; Iwaki, T. Age-Associated Prevalence and Risk Factors of Lewy Body Pathology in a General Population: The Hisayama Study. Acta Neuropathol. 2003, 106, 374–382. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ratnavel, A.; Dino, F.R.; Jiang, C.; Azmy, S.; Wyman-Chick, K.A.; Bayram, E. Risk Factors and Predictors for Lewy Body Dementia: A Systematic Review. npj Dement. 2025, 1, 20. [Google Scholar] [CrossRef] [Scilit]
- Prasad, S.; Katta, M.R.; Abhishek, S.; Sridhar, R.; Valisekka, S.S.; Hameed, M.; Kaur, J.; Walia, N. Recent Advances in Lewy Body Dementia: A Comprehensive Review. Dis.-A-Mon. 2023, 69, 101441. [Google Scholar] [CrossRef] [Scilit]
- Trétiakoff, K.N. Contribution à L’étude De L’anatomie Pathologique Du Locus Niger De Soemmering avec Quelques Deductions Relatives A La Pathogenie Des Troubles Du Tonus Musculaire et De La Maladie De Parkinson. Ph.D. Thesis, Universtié de Paris, Paris, France, 1919. [Google Scholar]
- Okazaki, H.; Lipkin, L.E.; Aronson, S.M. Diffuse Intracytoplasmic Ganglionic Inclusions (Lewy Type) Associated with Progressive Dementia and Quadriparesis in Flexion. J. Neuropathol. Exp. Neurol. 1961, 20, 237–244. [Google Scholar] [CrossRef] [Scilit]
- Kosaka, K.; Iseki, E. Dementia with Lewy Bodies. Curr. Opin. Neurol. 1996, 9, 271–275. [Google Scholar] [CrossRef] [Scilit]
- Kosaka, K. Lewy Bodies in Cerebral Cortex. Report of Three Cases. Acta Neuropathol. 1978, 42, 127–134. [Google Scholar] [CrossRef] [Scilit]
- McKeith, I.G.; Galasko, D.; Kosaka, K.; Perry, E.K.; Dickson, D.W.; Hansen, L.A.; Salmon, D.P.; Lowe, J.; Mirra, S.S.; Byrne, E.J.; et al. Consensus Guidelines for the Clinical and Pathologic Diagnosis of Dementia with Lewy Bodies (DLB): Report of the Consortium on DLB International Workshop. Neurology 1996, 47, 1113–1124. [Google Scholar] [CrossRef] [Scilit]
- Mueller, C.; Ballard, C.; Corbett, A.; Aarsland, D. Historical Landmarks in Dementia with Lewy Bodies. Lancet Neurol. 2017, 16, 348. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.-Y.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. α-Synuclein in Lewy Bodies. Nature 1997, 388, 839–840. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Coughlan, G.; Laczó, J.; Hort, J.; Minihane, A.-M.; Hornberger, M. Spatial Navigation Deficits—Overlooked Cognitive Marker for Preclinical Alzheimer Disease? Nat. Rev. Neurol. 2018, 14, 496–506. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Knopman, D.S.; Amieva, H.; Petersen, R.C.; Chételat, G.; Holtzman, D.M.; Hyman, B.T.; Nixon, R.A.; Jones, D.T. Alzheimer Disease. Nat. Rev. Dis. Primers 2021, 7, 33. [Google Scholar] [CrossRef] [Scilit]
- McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D.; Stadlan, E.M. Clinical Diagnosis of Alzheimer’s Disease: Report of the NINCDS—ADRDA Work Group under the Auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984, 34, 939–944. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R.; Kawas, C.H.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; et al. The Diagnosis of Dementia Due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease. Alzheimer’s Dement. 2011, 7, 263–269. [Google Scholar] [CrossRef] [Scilit]
- Jack, C.R.; Andrews, J.S.; Beach, T.G.; Buracchio, T.; Dunn, B.; Graf, A.; Hansson, O.; Ho, C.; Jagust, W.; McDade, E.; et al. Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease: Alzheimer’s Association Workgroup. Alzheimer’s Dement. 2024, 20, 5143–5169. [Google Scholar] [CrossRef] [Scilit]
- Jack, C.R.; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Dunn, B.; Haeberlein, S.B.; Holtzman, D.M.; Jagust, W.; Jessen, F.; Karlawish, J.; et al. NIA-AA Research Framework: Toward a Biological Definition of Alzheimer’s Disease. Alzheimer’s Dement. 2018, 14, 535–562. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Porsteinsson, A.P.; Isaacson, R.S.; Knox, S.; Sabbagh, M.N.; Rubino, I. Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021. J. Prev. Alzheimer’s Dis. 2021, 8, 371–386. [Google Scholar] [CrossRef] [Scilit]
- Donaghy, P.C.; McKeith, I.G. The Clinical Characteristics of Dementia with Lewy Bodies and a Consideration of Prodromal Diagnosis. Alzheimer’s Res. Ther. 2014, 6, 46. [Google Scholar] [CrossRef] [Scilit]
- Yamada, M.; Komatsu, J.; Nakamura, K.; Sakai, K.; Samuraki-Yokohama, M.; Nakajima, K.; Yoshita, M. Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions. J. Mov. Dis. 2020, 13, 1–10. [Google Scholar] [CrossRef] [Scilit]
- McKeith, I.G.; Boeve, B.F.; Dickson, D.W.; Halliday, G.; Taylor, J.-P.; Weintraub, D.; Aarsland, D.; Galvin, J.; Attems, J.; Ballard, C.G.; et al. Diagnosis and Management of Dementia with Lewy Bodies: Fourth Consensus Report of the DLB Consortium. Neurology 2017, 89, 88–100. [Google Scholar] [CrossRef] [Scilit]
- Bencze, J.; Seo, W.; Hye, A.; Aarsland, D.; Hortobágyi, T. Dementia with Lewy Bodies—A Clinicopathological Update. Free Neuropathol. 2020, 1, 7. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Beach, T.G.; Serrano, G.E.; Zhang, N.; Driver-Dunckley, E.D.; Sue, L.I.; Shill, H.A.; Mehta, S.H.; Belden, C.; Tremblay, C.; Choudhury, P.; et al. Clinicopathological Heterogeneity of Lewy Body Diseases: The Profound Influence of Comorbid Alzheimer’s Disease. medRxiv 2024. preprint. [Google Scholar] [CrossRef] [Scilit]
- McKeith, I.G.; Dickson, D.W.; Lowe, J.; Emre, M.; O’Brien, J.T.; Feldman, H.; Cummings, J.; Duda, J.E.; Lippa, C.; Perry, E.K.; et al. Diagnosis and Management of Dementia with Lewy Bodies: Third Report of the DLB Consortium. Neurology 2005, 65, 1863–1872, Erratum in: Neurology 2005, 65, 1992. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Laczó, M.; Svacova, Z.; Lerch, O.; Martinkovic, L.; Krejci, M.; Nedelska, Z.; Horakova, H.; Matoska, V.; Vyhnalek, M.; Hort, J.; et al. Spatial Navigation Deficits in Early Alzheimer’s Disease: The Role of Biomarkers and APOE Genotype. J. Neurol. 2025, 272, 438. [Google Scholar] [CrossRef] [Scilit]
- Liang, J.; Li, R.; Wong, G.; Huang, X. Lewy Body Dementia: Exploring Biomarkers and Pathogenic Interactions of Amyloid β, Tau, and α-Synuclein. Mol. Neurodegener. 2025, 20, 90. [Google Scholar] [CrossRef] [Scilit]
- Rongve, A.; Soennesyn, H.; Skogseth, R.; Oesterhus, R.; Hortobágyi, T.; Ballard, C.; Auestad, B.H.; Aarsland, D. Cognitive Decline in Dementia with Lewy Bodies: A 5-Year Prospective Cohort Study. BMJ Open 2016, 6, e010357. [Google Scholar] [CrossRef] [Scilit]
- Mirza, S.S.; Saeed, U.; Ramirez, J.; Herrmann, N.; Stuss, D.T.; Black, S.E.; Masellis, M. Effects of White Matter Hyperintensities, Neuropsychiatric Symptoms, and Cognition on Activities of Daily Living: Differences between Alzheimer’s Disease and Dementia with Lewy Bodies. Alzheimer’s Dement. 2022, 14, e12306. [Google Scholar] [CrossRef] [Scilit]
- Wiese, L.K.; Lingler, J.; Lindauer, A. Alzheimer’s Disease and Lewy Body Dementia: Discerning the Differences. Am. Nurse J. 2022, 16, 10–17. [Google Scholar]
- Gibson, L.L.; Skogseth, R.E.; Hortobagyi, T.; Vik-Mo, A.O.; Ballard, C.; Aarsland, D. Clinical Evolution of Neuropsychiatric Symptoms in Alzheimer’s Disease and Dementia With Lewy Bodies in a Post-Mortem Cohort. Int. J. Geriatr. Psychiatry 2025, 40, e70084. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- DeTure, M.A.; Dickson, D.W. The Neuropathological Diagnosis of Alzheimer’s Disease. Mol. Neurodegener. 2019, 14, 32. [Google Scholar] [CrossRef] [Scilit]
- Perl, D.P. Neuropathology of Alzheimer’s Disease. Mt. Sinai J. Med. 2010, 77, 32–42. [Google Scholar] [CrossRef] [Scilit]
- Dickerson, B.C.; Bakkour, A.; Salat, D.H.; Feczko, E.; Pacheco, J.; Greve, D.N.; Grodstein, F.; Wright, C.I.; Blacker, D.; Rosas, H.D.; et al. The Cortical Signature of Alzheimer’s Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and Is Detectable in Asymptomatic Amyloid-Positive Individuals. Cereb. Cortex 2009, 19, 497–510. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Arriagada, P.V.; Growdon, J.H.; Hedley-Whyte, E.T.; Hyman, B.T. Neurofibrillary Tangles but Not Senile Plaques Parallel Duration and Severiti of Azheimer’s Disease. Neurology 1992, 42 Pt 1, 631–639. [Google Scholar] [CrossRef] [Scilit]
- Browne, D.F.; Smirnov, D.S.; Coughlin, D.G.; Peng, I.; Standke, H.G.; Kim, Y.; Pizzo, D.P.; Unapanta, A.; Andreasson, T.; Hiniker, A.; et al. Early Alzheimer’s Disease with Frequent Neuritic Plaques Harbors Neocortical Tau Seeds Distinct from Primary Age-Related Tauopathy. Nat. Commun. 2025, 16, 1851. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wang, J.-Z.; Xia, Y.-Y.; Grundke-Iqbal, I.; Iqbal, K. Abnormal Hyperphosphorylation of Tau: Sites, Regulation, and Molecular Mechanism of Neurofibrillary Degeneration. J. Mov. Dis. 2012, 33, S123–S139. [Google Scholar] [CrossRef] [Scilit]
- Braak, H.; Braak, E. Neuropathological Stageing of Alzheimer-Related Changes. Acta Neuropathol. 1991, 82, 239–259. [Google Scholar] [CrossRef] [Scilit]
- Braak, H.; Alafuzoff, I.; Arzberger, T.; Kretzschmar, H.; Del Tredici, K. Staging of Alzheimer Disease-Associated Neurofibrillary Pathology Using Paraffin Sections and Immunocytochemistry. Acta Neuropathol. 2006, 112, 389–404. [Google Scholar] [CrossRef] [Scilit]
- Chen, S.-D.; Lu, J.-Y.; Li, H.-Q.; Yang, Y.-X.; Jiang, J.-H.; Cui, M.; Zuo, C.-T.; Tan, L.; Dong, Q.; Yu, J.-T.; et al. Staging Tau Pathology with Tau PET in Alzheimer’s Disease: A Longitudinal Study. Transl. Psychiatry 2021, 11, 483. [Google Scholar] [CrossRef] [Scilit]
- Thal, D.R.; Rüb, U.; Orantes, M.; Braak, H. Phases of Aβ-Deposition in the Human Brain and Its Relevance for the Development of AD. Neurology 2002, 58, 1791–1800. [Google Scholar] [CrossRef] [Scilit]
- Montine, T.J.; Phelps, C.H.; Beach, T.G.; Bigio, E.H.; Cairns, N.J.; Dickson, D.W.; Duyckaerts, C.; Frosch, M.P.; Masliah, E.; Mirra, S.S.; et al. National Institute on Aging–Alzheimer’s Association Guidelines for the Neuropathologic Assessment of Alzheimer’s Disease: A Practical Approach. Acta Neuropathol. 2012, 123, 1–11. [Google Scholar] [CrossRef] [Scilit]
- Bencze, J.; Szarka, M.; Bencs, V.; Szabó, R.N.; Smajda, M.; Aarsland, D.; Hortobágyi, T. Neuropathological Characterization of Lemur Tyrosine Kinase 2 (LMTK2) in Alzheimer’s Disease and Neocortical Lewy Body Disease. Sci. Rep. 2019, 9, 17222. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Nedelska, Z.; Ferman, T.J.; Boeve, B.F.; Przybelski, S.A.; Lesnick, T.G.; Murray, M.E.; Gunter, J.L.; Senjem, M.L.; Vemuri, P.; Smith, G.E.; et al. Pattern of Brain Atrophy Rates in Autopsy-Confirmed Dementia with Lewy Bodies. Neurobiol. Aging 2015, 36, 452–461. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Harper, L.; Fumagalli, G.G.; Barkhof, F.; Scheltens, P.; O’Brien, J.T.; Bouwman, F.; Burton, E.J.; Rohrer, J.D.; Fox, N.C.; Ridgway, G.R.; et al. MRI Visual Rating Scales in the Diagnosis of Dementia: Evaluation in 184 Post-Mortem Confirmed Cases. Brain 2016, 139, 1211–1225. [Google Scholar] [CrossRef] [Scilit]
- Attems, J.; Toledo, J.B.; Walker, L.; Gelpi, E.; Gentleman, S.; Halliday, G.; Hortobagyi, T.; Jellinger, K.; Kovacs, G.G.; Lee, E.B.; et al. Neuropathological Consensus Criteria for the Evaluation of Lewy Pathology in Post-Mortem Brains: A Multi-Centre Study. Acta Neuropathol. 2021, 141, 159–172. [Google Scholar] [CrossRef] [Scilit]
- Kanazawa, T.; Uchihara, T.; Takahashi, A.; Nakamura, A.; Orimo, S.; Mizusawa, H. Three-Layered Structure Shared Between Lewy Bodies and Lewy Neurites—Three-Dimensional Reconstruction of Triple-Labeled Sections. Brain Pathol. 2008, 18, 415–422. [Google Scholar] [CrossRef] [Scilit]
- Koga, S.; Sekiya, H.; Kondru, N.; Ross, O.A.; Dickson, D.W. Neuropathology and Molecular Diagnosis of Synucleinopathies. Mol. Neurodegener. 2021, 16, 83. [Google Scholar] [CrossRef] [Scilit]
- Amin, J.; Holmes, C.; Dorey, R.B.; Tommasino, E.; Casal, Y.R.; Williams, D.M.; Dupuy, C.; Nicoll, J.A.R.; Boche, D. Neuroinflammation in Dementia with Lewy Bodies: A Human Post-Mortem Study. Transl. Psychiatry 2020, 10, 267. [Google Scholar] [CrossRef] [Scilit]
- Burton, E.J.; Karas, G.; Paling, S.M.; Barber, R.; Williams, E.D.; Ballard, C.G.; McKeith, I.G.; Scheltens, P.; Barkhof, F.; O’Brien, J.T. Patterns of Cerebral Atrophy in Dementia with Lewy Bodies Using Voxel-Based Morphometry. NeuroImage 2002, 17, 618–630. [Google Scholar] [CrossRef]
- Burton, E.J.; Barber, R.; Mukaetova-Ladinska, E.B.; Robson, J.; Perry, R.H.; Jaros, E.; Kalaria, R.N.; O’Brien, J.T. Medial Temporal Lobe Atrophy on MRI Differentiates Alzheimer’s Disease from Dementia with Lewy Bodies and Vascular Cognitive Impairment: A Prospective Study with Pathological Verification of Diagnosis. Brain 2009, 132, 195–203. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Coughlin, D.G.; Hurtig, H.I.; Irwin, D.J. Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases. Mov. Disord. 2020, 35, 5–19. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Skogseth, R.; Hortobágyi, T.; Soennesyn, H.; Chwiszczuk, L.; Ffytche, D.; Rongve, A.; Ballard, C.; Aarsland, D. Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. J. Mov. Dis. 2017, 59, 1139–1152. [Google Scholar] [CrossRef] [Scilit]
- Röhr, S. Making Time for Brain Health: Recognising Temporal Inequity in Dementia Risk Reduction. Lancet Healthy Longev. 2025, 6, 100768. [Google Scholar] [CrossRef] [Scilit]
- Yegambaram, M.; Manivannan, B.; Beach, T.; Halden, R. Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review. Cur. Alzheimer Res. 2015, 12, 116–146. [Google Scholar] [CrossRef] [Scilit]
- Chin-Chan, M.; Navarro-Yepes, J.; Quintanilla-Vega, B. Environmental Pollutants as Risk Factors for Neurodegenerative Disorders: Alzheimer and Parkinson Diseases. Front. Cell. Neurosci. 2015, 9, 124. [Google Scholar] [CrossRef] [Scilit]
- Giridharan, V.V.; Masud, F.; Petronilho, F.; Dal-Pizzol, F.; Barichello, T. Infection-Induced Systemic Inflammation Is a Potential Driver of Alzheimer’s Disease Progression. Front. Aging Neurosci. 2019, 11, 122. [Google Scholar] [CrossRef] [Scilit]
- Tanzi, R.E. The Genetics of Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2012, 2, a006296. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bellenguez, C.; Grenier-Boley, B.; Lambert, J.-C. Genetics of Alzheimer’s Disease: Where We Are, and Where We Are Going. Curr. Opin. Neurobiol. 2020, 61, 40–48. [Google Scholar] [CrossRef] [Scilit]
- Bellenguez, C.; Küçükali, F.; Jansen, I.E.; Kleineidam, L.; Moreno-Grau, S.; Amin, N.; Naj, A.C.; Campos-Martin, R.; Grenier-Boley, B.; Andrade, V.; et al. New Insights into the Genetic Etiology of Alzheimer’s Disease and Related Dementias. Nat. Genet. 2022, 54, 412–436. [Google Scholar] [CrossRef] [Scilit]
- Korologou-Linden, R.; Bhatta, L.; Brumpton, B.M.; Howe, L.D.; Millard, L.A.C.; Kolaric, K.; Ben-Shlomo, Y.; Williams, D.M.; Smith, G.D.; Anderson, E.L.; et al. The Causes and Consequences of Alzheimer’s Disease: Phenome-Wide Evidence from Mendelian Randomization. Nat. Commun. 2022, 13, 4726. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mitra, S.; Bp, K.; C R, S.; Saikumar, N.V.; Philip, P.; Narayanan, M. Alzheimer’s Disease Rewires Gene Coexpression Networks Coupling Different Brain Regions. npj Syst. Biol. Appl. 2024, 10, 50. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kamatham, P.T.; Shukla, R.; Khatri, D.K.; Vora, L.K. Pathogenesis, Diagnostics, and Therapeutics for Alzheimer’s Disease: Breaking the Memory Barrier. Ageing Res. Rev. 2024, 101, 102481. [Google Scholar] [CrossRef] [Scilit]
- Härtig, W.; Bauer, A.; Brauer, K.; Grosche, J.; Hortobágyi, T.; Penke, B.; Schliebs, R.; Harkany, T. Functional Recovery of Cholinergic Basal Forebrain Neurons under Disease Conditions: Old Problems, New Solutions? Rev. Neurosci. 2002, 13, 95–165. [Google Scholar] [CrossRef] [Scilit]
- Jellinger, K.A. Dementia with Lewy Bodies and Parkinson’s Disease-Dementia: Current Concepts and Controversies. J. Neural Transm. 2018, 125, 615–650. [Google Scholar] [CrossRef] [Scilit]
- Agin, A.; Blanc, F.; Bousiges, O.; Villette, C.; Philippi, N.; Demuynck, C.; Martin-Hunyadi, C.; Cretin, B.; Lang, S.; Zumsteg, J.; et al. Environmental Exposure to Phthalates and Dementia with Lewy Bodies: Contribution of Metabolomics. J. Neurol. Neurosurg. Psychiatry 2020, 91, 968–974. [Google Scholar] [CrossRef] [Scilit]
- Zhao, Y.-L.; Qu, Y.; Ou, Y.-N.; Zhang, Y.-R.; Tan, L.; Yu, J.-T. Environmental Factors and Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis. Ageing Res. Rev. 2021, 72, 101504. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhang, X.; Liu, H.; Wu, X.; Jia, L.; Gadhave, K.; Wang, L.; Zhang, K.; Li, H.; Chen, R.; Kumbhar, R.; et al. Lewy Body Dementia Promotion by Air Pollutants. Science 2025, 389, eadu4132. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chia, R.; Sabir, M.S.; Bandres-Ciga, S.; Saez-Atienzar, S.; Reynolds, R.H.; Gustavsson, E.; Walton, R.L.; Ahmed, S.; Viollet, C.; Ding, J.; et al. Genome Sequencing Analysis Identifies New Loci Associated with Lewy Body Dementia and Provides Insights into Its Genetic Architecture. Nat. Genet. 2021, 53, 294–303. [Google Scholar] [CrossRef] [Scilit]
- Kaivola, K.; Shah, Z.; Chia, R.; International LBD Genomics Consortium; Black, S.E.; Gan-Or, Z.; Keith, J.; Masellis, M.; Rogaeva, E.; Brice, A.; et al. Genetic Evaluation of Dementia with Lewy Bodies Implicates Distinct Disease Subgroups. Brain 2022, 145, 1757–1762, Erratum in: Brain 2023, 146, e62–e63. https://doi.org/10.1093/brain/awad103. [Google Scholar] [CrossRef] [Scilit]
- Nalls, M.A.; Blauwendraat, C.; Vallerga, C.L.; Heilbron, K.; Bandres-Ciga, S.; Chang, D.; Tan, M.; Kia, D.A.; Noyce, A.J.; Xue, A.; et al. Identification of Novel Risk Loci, Causal Insights, and Heritable Risk for Parkinson’s Disease: A Meta-Analysis of Genome-Wide Association Studies. Lancet Neurol. 2019, 18, 1091–1102. [Google Scholar] [CrossRef] [Scilit]
- Talyansky, S.; Le Guen, Y.; Kasireddy, N.; Belloy, M.E.; Greicius, M.D. APOE-Ε4 and BIN1 Increase Risk of Alzheimer’s Disease Pathology but Not Specifically of Lewy Body Pathology. Acta Neuropathol. Commun. 2023, 11, 149. [Google Scholar] [CrossRef] [Scilit]
- Guerreiro, R.; Ross, O.A.; Kun-Rodrigues, C.; Hernandez, D.G.; Orme, T.; Eicher, J.D.; Shepherd, C.E.; Parkkinen, L.; Darwent, L.; Heckman, M.G.; et al. Investigating the Genetic Architecture of Dementia with Lewy Bodies: A Two-Stage Genome-Wide Association Study. Lancet Neurol. 2018, 17, 64–74. [Google Scholar] [CrossRef] [Scilit]
- Hardy, J.A.; Higgins, G.A. Alzheimer’s Disease: The Amyloid Cascade Hypothesis. Science 1992, 256, 184–185. [Google Scholar] [CrossRef] [Scilit]
- Selkoe, D.J.; Hardy, J. The Amyloid Hypothesis of Alzheimer’s Disease at 25 Years. EMBO Mol. Med. 2016, 8, 595–608. [Google Scholar] [CrossRef] [Scilit]
- Chen, X.-Q.; Mobley, W.C. Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses. Front. Neurosci. 2019, 13, 446. [Google Scholar] [CrossRef] [Scilit]
- Meyer-Luehmann, M.; Spires-Jones, T.L.; Prada, C.; Garcia-Alloza, M.; De Calignon, A.; Rozkalne, A.; Koenigsknecht-Talboo, J.; Holtzman, D.M.; Bacskai, B.J.; Hyman, B.T. Rapid Appearance and Local Toxicity of Amyloid-β Plaques in a Mouse Model of Alzheimer’s Disease. Nature 2008, 451, 720–724. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Suzuki, N.; Cheung, T.T.; Cai, X.-D.; Odaka, A.; Otvos, L.; Eckman, C.; Golde, T.E.; Younkin, S.G. An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βApp717) Mutants. Science 1994, 264, 1336–1340. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Murphy, M.P.; LeVine, H. Alzheimer’s Disease and the Amyloid-β Peptide. J. Mov. Dis. 2010, 19, 311–323. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Francis, P.T.; Palmer, A.M.; Snape, M.; Wilcock, G.K. The Cholinergic Hypothesis of Alzheimer’s Disease: A Review of Progress. J. Neurol. Neurosurg. Psychiatry 1999, 66, 137–147. [Google Scholar] [CrossRef] [Scilit]
- Hampel, H.; Mesulam, M.-M.; Cuello, A.C.; Khachaturian, A.S.; Vergallo, A.; Farlow, M.R.; Snyder, P.J.; Giacobini, E.; Khachaturian, Z.S. Revisiting the Cholinergic Hypothesis in Alzheimer’s Disease: Emerging Evidence from Translational and Clinical Research. J. Prev. Alzheimer’s Dis. 2019, 6, 2–15. [Google Scholar] [CrossRef] [Scilit]
- Avila, J.; Lucas, J.J.; Pérez, M.; Hernández, F. Role of Tau Protein in Both Physiological and Pathological Conditions. Physiol. Rev. 2004, 84, 361–384. [Google Scholar] [CrossRef] [Scilit]
- Alonso, A.D.C.; Grundke-Iqbal, I.; Iqbal, K. Alzheimer’s Disease Hyperphosphorylated Tau Sequesters Normal Tau into Tangles of Filaments and Disassembles Microtubules. Nat. Med. 1996, 2, 783–787. [Google Scholar] [CrossRef] [Scilit]
- Moloney, C.M.; Lowe, V.J.; Murray, M.E. Visualization of Neurofibrillary Tangle Maturity in Alzheimer’s Disease: A Clinicopathologic Perspective for Biomarker Research. Alzheimer’s Dement. 2021, 17, 1554–1574. [Google Scholar] [CrossRef] [Scilit]
- Aguzzi, A.; Lakkaraju, A.K.K. Cell Biology of Prions and Prionoids: A Status Report. Trends Cell Biol. 2016, 26, 40–51. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Vasconcelos, B.; Stancu, I.-C.; Buist, A.; Bird, M.; Wang, P.; Vanoosthuyse, A.; Van Kolen, K.; Verheyen, A.; Kienlen-Campard, P.; Octave, J.-N.; et al. Heterotypic Seeding of Tau Fibrillization by Pre-Aggregated Abeta Provides Potent Seeds for Prion-like Seeding and Propagation of Tau-Pathology in Vivo. Acta Neuropathol. 2016, 131, 549–569. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bloom, G.S. Amyloid-β and Tau: The Trigger and Bullet in Alzheimer Disease Pathogenesis. JAMA Neurol. 2014, 71, 505. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- McAleese, K.E.; Walker, L.; Erskine, D.; Thomas, A.J.; McKeith, I.G.; Attems, J. TDP-43 Pathology in Alzheimer’s Disease, Dementia with Lewy Bodies and Ageing. Brain Pathol. 2017, 27, 472–479. [Google Scholar] [CrossRef] [Scilit]
- Simon, C.; Soga, T.; Okano, H.J.; Parhar, I. α-Synuclein-Mediated Neurodegeneration in Dementia with Lewy Bodies: The Pathobiology of a Paradox. Cell Biosci. 2021, 11, 196. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Neupane, S.; De Cecco, E.; Aguzzi, A. The Hidden Cell-to-Cell Trail of α-Synuclein Aggregates. J. Mol. Biol. 2022, 167930. [Google Scholar] [CrossRef] [Scilit]
- Ayers, J.I.; Lee, J.; Monteiro, O.; Woerman, A.L.; Lazar, A.A.; Condello, C.; Paras, N.A.; Prusiner, S.B. Different α-Synuclein Prion Strains Cause Dementia with Lewy Bodies and Multiple System Atrophy. Proc. Natl. Acad. Sci. USA 2022, 119, e2113489119. [Google Scholar] [CrossRef] [Scilit]
- Serdiuk, T.; Redeker, V.; Savistchenko, J.; Neupane, S.; Haenseler, W.; Fleischmann, Y.; Reber, V.; Keller, S.; Tiberi, C.; Bachmann-Gagescu, R.; et al. Structure-Function Relationship of Alpha-Synuclein Fibrillar Polymorphs Derived from Distinct Synucleinopathies. bioRxiv 2025. [Google Scholar] [CrossRef] [Scilit]
- Van Der Perren, A.; Gelders, G.; Fenyi, A.; Bousset, L.; Brito, F.; Peelaerts, W.; Van Den Haute, C.; Gentleman, S.; Melki, R.; Baekelandt, V. The Structural Differences between Patient-Derived α-Synuclein Strains Dictate Characteristics of Parkinson’s Disease, Multiple System Atrophy and Dementia with Lewy Bodies. Acta Neuropathol. 2020, 139, 977–1000. [Google Scholar] [CrossRef] [Scilit]
- Guo, J.L.; Covell, D.J.; Daniels, J.P.; Iba, M.; Stieber, A.; Zhang, B.; Riddle, D.M.; Kwong, L.K.; Xu, Y.; Trojanowski, J.Q.; et al. Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons. Cell 2013, 154, 103–117. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bassil, F.; Brown, H.J.; Pattabhiraman, S.; Iwasyk, J.E.; Maghames, C.M.; Meymand, E.S.; Cox, T.O.; Riddle, D.M.; Zhang, B.; Trojanowski, J.Q.; et al. Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology. Neuron 2020, 105, 260–275.e6. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zempel, H.; Thies, E.; Mandelkow, E.; Mandelkow, E.-M. Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines. J. Neurosci. 2010, 30, 11938–11950, Erratum in: J. Neurosci. 2012, 32, 6052. [Google Scholar] [CrossRef] [Scilit]
- Giasson, B.I.; Forman, M.S.; Higuchi, M.; Golbe, L.I.; Graves, C.L.; Kotzbauer, P.T.; Trojanowski, J.Q.; Lee, V.M.-Y. Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein. Science 2003, 300, 636–640. [Google Scholar] [CrossRef] [Scilit]
- Williams, T.; Sorrentino, Z.; Weinrich, M.; Giasson, B.I.; Chakrabarty, P. Differential Cross-Seeding Properties of Tau and α-Synuclein in Mouse Models of Tauopathy and Synucleinopathy. Brain Commun. 2020, 2, fcaa090. [Google Scholar] [CrossRef] [Scilit]
- Clinton, L.K.; Blurton-Jones, M.; Myczek, K.; Trojanowski, J.Q.; LaFerla, F.M. Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline. J. Neurosci. 2010, 30, 7281–7289. [Google Scholar] [CrossRef] [Scilit]
- Singh, A.; Kukreti, R.; Saso, L.; Kukreti, S. Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules 2019, 24, 1583. [Google Scholar] [CrossRef] [Scilit]
- Leuner, K.; Schütt, T.; Kurz, C.; Eckert, S.H.; Schiller, C.; Occhipinti, A.; Mai, S.; Jendrach, M.; Eckert, G.P.; Kruse, S.E.; et al. Mitochondrion-Derived Reactive Oxygen Species Lead to Enhanced Amyloid Beta Formation. Antioxid. Redox Signal. 2012, 16, 1421–1433. [Google Scholar] [CrossRef] [Scilit]
- Swerdlow, R.H. The Alzheimer’s Disease Mitochondrial Cascade Hypothesis: A Current Overview. J. Alzheimer’s Dis. 2023, 92, 751–768. [Google Scholar] [CrossRef] [Scilit]
- Hsu, L.J.; Sagara, Y.; Arroyo, A.; Rockenstein, E.; Sisk, A.; Mallory, M.; Wong, J.; Takenouchi, T.; Hashimoto, M.; Masliah, E. α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress. Am. J. Pathol. 2000, 157, 401–410. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Billingsley, K.J.; Barbosa, I.A.; Bandrés-Ciga, S.; Quinn, J.P.; Bubb, V.J.; Deshpande, C.; Botia, J.A.; Reynolds, R.H.; Zhang, D.; Simpson, M.A.; et al. Mitochondria Function Associated Genes Contribute to Parkinson’s Disease Risk and Later Age at Onset. npj Park. Dis. 2019, 5, 8. [Google Scholar] [CrossRef] [Scilit]
- Spano, M. The Possible Involvement of Mitochondrial Dysfunctions in Lewy Body Dementia: A Systematic Review. Funct. Neurol. 2015, 30, 151–158. [Google Scholar] [CrossRef] [Scilit]
- Ye, J.; Dai, X.; Zhang, C.; Duan, Z.; Zhou, G.; Wang, J. Investigating the Causal Relationships between Mitochondrial Proteins and Dementia with Lewy Bodies. J. Alzheimer’s Dis. 2025, 105, 378–386. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Millot, P.; Pujol, C.; Paquet, C.; Mouton-Liger, F. Impaired Mitochondrial Dynamics in the Blood of Patients with Alzheimer’s Disease and Lewy Body Dementia. Alzheimer’s Dement. 2023, 19, e075795. [Google Scholar] [CrossRef] [Scilit]
- Heneka, M.T.; Carson, M.J.; Khoury, J.E.; Landreth, G.E.; Brosseron, F.; Feinstein, D.L.; Jacobs, A.H.; Wyss-Coray, T.; Vitorica, J.; Ransohoff, R.M.; et al. Neuroinflammation in Alzheimer’s Disease. Lancet Neurol. 2015, 14, 388–405. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wang, W.-Y.; Tan, M.-S.; Yu, J.-T.; Tan, L. Role of Pro-Inflammatory Cytokines Released from Microglia in Alzheimer’s Disease. Ann. Transl. Med. 2015, 3, 136. [Google Scholar]
- Griciuc, A.; Patel, S.; Federico, A.N.; Choi, S.H.; Innes, B.J.; Oram, M.K.; Cereghetti, G.; McGinty, D.; Anselmo, A.; Sadreyev, R.I.; et al. TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer’s Disease. Neuron 2019, 103, 820–835.e7. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Heneka, M.T.; Van Der Flier, W.M.; Jessen, F.; Hoozemanns, J.; Thal, D.R.; Boche, D.; Brosseron, F.; Teunissen, C.; Zetterberg, H.; Jacobs, A.H.; et al. Neuroinflammation in Alzheimer Disease. Nat. Rev. Immunol. 2025, 25, 321–352. [Google Scholar] [CrossRef] [Scilit]
- Plantone, D.; Pardini, M.; Righi, D.; Manco, C.; Colombo, B.M.; De Stefano, N. The Role of TNF-α in Alzheimer’s Disease: A Narrative Review. Cells 2023, 13, 54. [Google Scholar] [CrossRef] [Scilit]
- Wenzel, T.J.; Murray, T.E.; Noyovitz, B.; Narayana, K.; Gray, T.E.; Le, J.; He, J.; Simtchouk, S.; Gibon, J.; Alcorn, J.; et al. Cardiolipin Released by Microglia Can Act on Neighboring Glial Cells to Facilitate the Uptake of Amyloid-β (1–42). Mol. Cell. Neurosci. 2023, 124, 103804. [Google Scholar] [CrossRef] [Scilit]
- Jellinger, K.A.; Attems, J. Prevalence and Impact of Vascular and Alzheimer Pathologies in Lewy Body Disease. Acta Neuropathol. 2008, 115, 427–436. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jellinger, K.A. Alzheimer Disease and Cerebrovascular Pathology: An Update. J. Neural Transm. 2002, 109, 813–836. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Attems, J.; Jellinger, K.A. Only Cerebral Capillary Amyloid Angiopathy Correlates with Alzheimer Pathology? A Pilot Study. Acta Neuropathol. 2004, 107, 83–90. [Google Scholar] [CrossRef] [Scilit]
- Rajeev, V.; Fann, D.Y.; Dinh, Q.N.; Kim, H.A.; De Silva, T.M.; Lai, M.K.P.; Chen, C.L.-H.; Drummond, G.R.; Sobey, C.G.; Arumugam, T.V. Pathophysiology of Blood Brain Barrier Dysfunction during Chronic Cerebral Hypoperfusion in Vascular Cognitive Impairment. Theranostics 2022, 12, 1639–1658. [Google Scholar] [CrossRef] [Scilit]
- Zenaro, E.; Piacentino, G.; Constantin, G. The Blood-Brain Barrier in Alzheimer’s Disease. Neurobiol. Dis. 2017, 107, 41–56. [Google Scholar] [CrossRef] [Scilit]
- Candelario-Jalil, E.; Dijkhuizen, R.M.; Magnus, T. Neuroinflammation, Stroke, Blood-Brain Barrier Dysfunction, and Imaging Modalities. Stroke 2022, 53, 1473–1486. [Google Scholar] [CrossRef] [Scilit]
- Zhang, S.; Gao, Y.; Zhao, Y.; Huang, T.Y.; Zheng, Q.; Wang, X. Peripheral and Central Neuroimmune Mechanisms in Alzheimer’s Disease Pathogenesis. Mol. Neurodegener. 2025, 20, 22. [Google Scholar] [CrossRef] [Scilit]
- Cechetto, D.F.; Hachinski, V.; Whitehead, S.N. Vascular Risk Factors and Alzheimer’s Disease. Expert Rev. Neurother. 2008, 8, 743–750. [Google Scholar] [CrossRef] [Scilit]
- Surendranathan, A.; Rowe, J.B.; O’Brien, J.T. Neuroinflammation in Lewy Body Dementia. Park. Relat. Disord. 2015, 21, 1398–1406. [Google Scholar] [CrossRef] [Scilit]
- Rajkumar, A.P.; Bidkhori, G.; Shoaie, S.; Clarke, E.; Morrin, H.; Hye, A.; Williams, G.; Ballard, C.; Francis, P.; Aarsland, D. Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. Am. J. Geriatr. Psychiatry 2020, 28, 75–86. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jellinger, K.A. Prevalence of Vascular Lesions in Dementia with Lewy Bodies. A Postmortem Study. J. Neural Transm. 2003, 110, 771–778. [Google Scholar] [CrossRef] [Scilit]
- Johnson, E.C.B.; Carter, E.K.; Dammer, E.B.; Duong, D.M.; Gerasimov, E.S.; Liu, Y.; Liu, J.; Betarbet, R.; Ping, L.; Yin, L.; et al. Large-Scale Deep Multi-Layer Analysis of Alzheimer’s Disease Brain Reveals Strong Proteomic Disease-Related Changes Not Observed at the RNA Level. Nat. Neurosci. 2022, 25, 213–225. [Google Scholar] [CrossRef] [Scilit]
- Mathys, H.; Davila-Velderrain, J.; Peng, Z.; Gao, F.; Mohammadi, S.; Young, J.Z.; Menon, M.; He, L.; Abdurrob, F.; Jiang, X.; et al. Single-Cell Transcriptomic Analysis of Alzheimer’s Disease. Nature 2019, 570, 332–337, Erratum in: Nature 2019, 571, E1. [Google Scholar] [CrossRef] [Scilit]
- Knörnschild, F.; Zhang, E.J.; Ghosh Biswas, R.; Kobus, M.; Chen, J.; Zhou, J.X.; Rao, A.; Sun, J.; Wang, X.; Li, W.; et al. Correlations of Blood and Brain NMR Metabolomics with Alzheimer’s Disease Mouse Models. Transl. Psychiatry 2025, 15, 87. [Google Scholar] [CrossRef] [Scilit]
- Oka, T.; Matsuzawa, Y.; Tsuneyoshi, M.; Nakamura, Y.; Aoshima, K.; Tsugawa, H.; The Alzheimer’s Disease Metabolomics Consortium; Weiner, M.; Aisen, P.; Petersen, R.; et al. Multiomics Analysis to Explore Blood Metabolite Biomarkers in an Alzheimer’s Disease Neuroimaging Initiative Cohort. Sci. Rep. 2024, 14, 6797. [Google Scholar] [CrossRef] [Scilit]
- Greally, S.; Kumar, M.; Schlaffner, C.; Van Der Heijden, H.; Lawton, E.S.; Biswas, D.; Berretta, S.; Steen, H.; Steen, J.A. Dementia with Lewy Bodies Patients with High Tau Levels Display Unique Proteome Profiles. Mol. Neurodegener. 2024, 19, 98. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Goralski, T.M.; Meyerdirk, L.; Breton, L.; Brasseur, L.; Kurgat, K.; DeWeerd, D.; Turner, L.; Becker, K.; Adams, M.; Newhouse, D.J.; et al. Spatial Transcriptomics Reveals Molecular Dysfunction Associated with Cortical Lewy Pathology. Nat. Commun. 2024, 15, 2642. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pan, X.; Donaghy, P.C.; Roberts, G.; Chouliaras, L.; O’Brien, J.T.; Thomas, A.J.; Heslegrave, A.J.; Zetterberg, H.; McGuinness, B.; Passmore, A.P.; et al. Plasma Metabolites Distinguish Dementia with Lewy Bodies from Alzheimer’s Disease: A Cross-Sectional Metabolomic Analysis. Front. Aging Neurosci. 2024, 15, 1326780. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Canal-Garcia, A.; Branca, R.M.; Francis, P.T.; Ballard, C.; Winblad, B.; Lehtiö, J.; Nilsson, P.; Aarsland, D.; Pereira, J.B.; Bereczki, E. Proteomic Signatures of Alzheimer’s Disease and Lewy Body Dementias: A Comparative Analysis. Alzheimer’s Dement. 2025, 21, e14375. [Google Scholar] [CrossRef] [Scilit]
- Shantaraman, A.; Dammer, E.B.; Ugochukwu, O.; Duong, D.M.; Yin, L.; Carter, E.K.; Gearing, M.; Chen-Plotkin, A.; Lee, E.B.; Trojanowski, J.Q.; et al. Network Proteomics of the Lewy Body Dementia Brain Reveals Presynaptic Signatures Distinct from Alzheimer’s Disease. Mol. Neurodegener. 2024, 19, 60. [Google Scholar] [CrossRef] [Scilit]
- Habbal, S.; Mian, M.; Imam, M.; Tahiri, J.; Amor, A.; Reddy, P.H. Harnessing Artificial Intelligence for Transforming Dementia Care: Innovations in Early Detection and Treatment. Brain Organoid Syst. Neurosci. J. 2025, 3, 122–133. [Google Scholar] [CrossRef] [Scilit]
- Goddard, T.R.; Brookes, K.J.; Sharma, R.; Moemeni, A.; Rajkumar, A.P. Dementia with Lewy Bodies: Genomics, Transcriptomics, and Its Future with Data Science. Cells 2024, 13, 223. [Google Scholar] [CrossRef] [Scilit]
- Lian, P.; Guo, Y.; Yu, J. Biomarkers in Alzheimer’s Disease: Emerging Trends and Clinical Implications. Chin. Med. J. 2025, 138, 1009–1012. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jellinger, K.A. Criteria for the Neuropathological Diagnosis of Dementing Disorders: Routes out of the Swamp? Acta Neuropathol. 2009, 117, 101–110. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- McGettigan, S.; Nolan, Y.; Ghosh, S.; O’Mahony, D. The Emerging Role of Blood Biomarkers in Diagnosis and Treatment of Alzheimer’s Disease. Eur. Geriatr. Med. 2023, 14, 913–917. [Google Scholar] [CrossRef] [Scilit]
- Grande, G.; Valletta, M.; Rizzuto, D.; Xia, X.; Qiu, C.; Orsini, N.; Dale, M.; Andersson, S.; Fredolini, C.; Winblad, B.; et al. Blood-Based Biomarkers of Alzheimer’s Disease and Incident Dementia in the Community. Nat. Med. 2025, 31, 2027–2035. [Google Scholar] [CrossRef] [Scilit]
- Afrin, M.R.; Upadhyaya, P.G.; Hashim, A.; Bhattacharya, K.; Chanu, N.R.; Das, D.; Khanal, P.; Deka, S. Advanced Biomarkers: Beyond Amyloid and Tau: Emerging Non-Traditional Biomarkers for Alzheimer`s Diagnosis and Progression. Ageing Res. Rev. 2025, 108, 102736. [Google Scholar] [CrossRef] [Scilit]
- Polykretis, P.; Bessi, V.; Banchelli, M.; De Angelis, M.; Cecchi, C.; Nacmias, B.; Chiti, F.; D’Andrea, C.; Matteini, P. Fibrillar Structures Detected by AFM in the Cerebrospinal Fluid of Patients Affected by Alzheimer’s Disease and Other Neurological Conditions. Arch. Biochem. Biophys. 2025, 770, 110462. [Google Scholar] [CrossRef] [Scilit]
- Coutrot, A.; Schmidt, S.; Coutrot, L.; Pittman, J.; Hong, L.; Wiener, J.M.; Hölscher, C.; Dalton, R.C.; Hornberger, M.; Spiers, H.J. Virtual Navigation Tested on a Mobile App Is Predictive of Real-World Wayfinding Navigation Performance. PLoS ONE 2019, 14, e0213272. [Google Scholar] [CrossRef] [Scilit]
- Hansen, N.; Bouter, C.; Müller, S.J.; Van Riesen, C.; Khadhraoui, E.; Ernst, M.; Riedel, C.H.; Wiltfang, J.; Lange, C. New Insights into Potential Biomarkers in Patients with Mild Cognitive Impairment Occurring in the Prodromal Stage of Dementia with Lewy Bodies. Brain Sci. 2023, 13, 242. [Google Scholar] [CrossRef] [Scilit]
- Holden, S.K. Updates in Fluid, Tissue, and Imaging Biomarkers for Dementia with Lewy Bodies and Implications for Biologically Based Disease Definitions. Curr. Treat. Options Neurol. 2024, 26, 189–201. [Google Scholar] [CrossRef] [Scilit]
- Lashuel, H.A.; Surmeier, D.J.; Simuni, T.; Merchant, K.; Caughey, B.; Soto, C.; Fares, M.-B.; Heym, R.G.; Melki, R. Alpha-Synuclein Seed Amplification Assays: Data Sharing, Standardization Needed for Clinical Use. Sci. Adv. 2025, 11, eadt7195. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bsoul, R.; McWilliam, O.H.; Waldemar, G.; Hasselbalch, S.G.; Simonsen, A.H.; Von Buchwald, C.; Bech, M.; Pinborg, C.H.; Pedersen, C.K.; Baungaard, S.O.; et al. Accurate Detection of Pathologic α-Synuclein in CSF, Skin, Olfactory Mucosa, and Urine with a Uniform Seeding Amplification Assay. Acta Neuropathol. Commun. 2025, 13, 113. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sjaelland, N.S.; Gramkow, M.H.; Hasselbalch, S.G.; Frederiksen, K.S. Digital Biomarkers for the Assessment of Non-Cognitive Symptoms in Patients with Dementia with Lewy Bodies: A Systematic Review. J. Alzheimer’s Dis. 2024, 100, 431–451. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Del Campo, M.; Vermunt, L.; Peeters, C.F.W.; Sieben, A.; Hok-A-Hin, Y.S.; Lleó, A.; Alcolea, D.; Van Nee, M.; Engelborghs, S.; Van Alphen, J.L.; et al. CSF Proteome Profiling Reveals Biomarkers to Discriminate Dementia with Lewy Bodies from Alzheimer’s Disease. Nat. Commun. 2023, 14, 5635. [Google Scholar] [CrossRef] [Scilit]
- Jellinger, K.A. Comorbid Pathologies and Their Impact on Dementia with Lewy Bodies—Current View. Int. J. Mol. Sci. 2025, 26, 7674. [Google Scholar] [CrossRef] [Scilit]
- Marcuello, C.; Lim, K.; Nisini, G.; Pokrovsky, V.S.; Conde, J.; Ruggeri, F.S. Nanoscale Analysis beyond Imaging by Atomic Force Microscopy: Molecular Perspectives on Oncology and Neurodegeneration. Small Sci. 2025, 5, 2500351. [Google Scholar] [CrossRef] [Scilit]
- Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P.H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; et al. The Antibody Aducanumab Reduces Aβ Plaques in Alzheimer’s Disease. Nature 2016, 537, 50–56. [Google Scholar] [CrossRef] [Scilit]
- Neupane, S.; Nikolić, L.; Maraio, L.; Goiran, T.; Karpilovsky, N.; Sellitto, S.; Bouris, V.; Yin, J.-A.; Melki, R.; Fon, E.A.; et al. Large-Scale Bidirectional Arrayed Genetic Screens Identify OXR1 and EMC4 as Modifiers of α-Synuclein Aggregation. bioRxiv 2025. [Google Scholar] [CrossRef] [Scilit]
- Neupane, S.; Khadka, J.; Rayamajhi, S.; Pandey, A.S. Binding Modes of Potential Anti-Prion Phytochemicals to PrPC Structures in Silico. J. Ayurveda Integr. Med. 2023, 14, 100750. [Google Scholar] [CrossRef] [Scilit]
- Pacesa, M.; Nickel, L.; Schellhaas, C.; Schmidt, J.; Pyatova, E.; Kissling, L.; Barendse, P.; Choudhury, J.; Kapoor, S.; Alcaraz-Serna, A.; et al. One-Shot Design of Functional Protein Binders with BindCraft. Nature 2025, 646, 483–492. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

